Clovis Oncology Price to Book Ratio 2010-2021 | CLVS

Historical price to book ratio values for Clovis Oncology (CLVS) over the last 10 years. The current price to book ratio for Clovis Oncology as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Clovis Oncology Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 4.33 0.00
2021-06-30 5.80 $-1.75 -3.32
2021-03-31 7.02 $-2.11 -3.32
2020-12-31 4.80 $-1.53 -3.14
2020-09-30 5.83 $-1.85 -3.15
2020-06-30 6.75 $-1.10 -6.11
2020-03-31 6.36 $-1.73 -3.68
2019-12-31 10.43 $-3.17 -3.29
2019-09-30 3.93 $-1.60 -2.46
2019-06-30 14.87 $-0.56 -26.37
2019-03-31 24.82 $1.41 17.57
2018-12-31 17.96 $2.77 6.47
2018-09-30 29.37 $4.43 6.63
2018-06-30 45.47 $5.93 7.66
2018-03-31 52.80 $6.04 8.74
2017-12-31 68.00 $7.27 9.35
2017-09-30 82.40 $6.11 13.50
2017-06-30 93.63 $7.04 13.30
2017-03-31 63.67 $3.89 16.36
2016-12-31 44.42 $-0.09 -473.56
2016-09-30 36.05 $1.48 24.39
2016-06-30 13.72 $2.93 4.68
2016-03-31 19.20 $6.06 3.17
2015-12-31 35.00 $7.84 4.47
2015-09-30 91.99 $10.82 8.50
2015-06-30 87.88 $5.85 15.03
2015-03-31 74.23 $7.42 10.01
2014-12-31 56.00 $9.76 5.74
2014-09-30 45.36 $11.43 3.97
2014-06-30 41.41 $13.00 3.18
2014-03-31 69.27 $13.94 4.97
2013-12-31 60.27 $14.69 4.10
2013-09-30 60.80 $11.45 5.31
2013-06-30 66.98 $12.03 5.57
2013-03-31 28.67 $4.57 6.28
2012-12-31 16.00 $5.09 3.14
2012-09-30 20.45 $5.85 3.50
2012-06-30 21.68 $6.49 3.34
2012-03-31 25.45 $5.09 5.00
2011-12-31 14.09 $5.89 2.39
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.513B $0.165B
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76